scholarly journals Correction: Predicting Antituberculosis Drug–Induced Liver Injury Using an Interpretable Machine Learning Method: Model Development and Validation Study (Preprint)

2021 ◽  
Author(s):  
Daihai He
Keyword(s):  
Hong Kong ◽  
Model Development ◽  
Machine Learning Method ◽  
Learning Method ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
Development And Validation ◽  
Method Model ◽  
Applied Biology

UNSTRUCTURED Description: The corresponding author should be Shenyuan Liu. The 2 and 7 authors’ affiliation missing China. The 3-5 authors’ affiliation should be Department of Applied Biology and Chemical Technology, Hong Kong Polytechnic University, Hong Kong, China.

scholarly journals CYP2E1, GSTM1, and GSTT1 genetic polymorphisms and their associations with susceptibility to antituberculosis drug-induced liver injury in Thai tuberculosis patients

Heliyon ◽  
2021 ◽  
Vol 7 (4) ◽  
pp. e06852
Author(s):  
Noppadol Chanhom ◽  
Sukanya Wattanapokayakit ◽  
Nusara Satproedprai ◽  
Supharat Suvichapanich ◽  
Surakameth Mahasirimongkol ◽  
...  
Keyword(s):  
Liver Injury ◽  
Genetic Polymorphisms ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Tuberculosis Patients ◽  
Drug Induced Liver Injury

scholarly journals Outcomes of TB/HIV co-infected patients presenting with antituberculosis drug-induced liver injury

2015 ◽  
Vol 105 (5) ◽  
pp. 393 ◽  
Author(s):  
S Naidoo ◽  
D Evans ◽  
E Jong ◽  
K Mellet ◽  
R Berhanu
Keyword(s):  
Liver Injury ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Drug Induced Liver Injury

scholarly journals Genetic Risk Factors in Drug‐Induced Liver Injury Due to Isoniazid‐Containing Antituberculosis Drug Regimens

2020 ◽  
Author(s):  
Paola Nicoletti ◽  
Harshad Devarbhavi ◽  
Ashish Goel ◽  
Radha Venkatesan ◽  
Chundamannil E. Eapen ◽  
...  
Keyword(s):  
Risk Factors ◽  
Liver Injury ◽  
Genetic Risk ◽  
Genetic Risk Factors ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
Drug Regimens

scholarly journals Prophylactic Therapy of Silymarin (Milk Thistle) on Antituberculosis Drug-Induced Liver Injury: A Meta-Analysis of Randomized Controlled Trials

2019 ◽  
Vol 2019 ◽  
pp. 1-11 ◽  
Author(s):  
Lina Tao ◽  
Xiaoyu Qu ◽  
Yue Zhang ◽  
Yanqing Song ◽  
Si-xi Zhang
Keyword(s):  
Liver Injury ◽  
Liver Function ◽  
Randomized Controlled Trials ◽  
Controlled Trials ◽  
Cochrane Central Register ◽  
Prophylactic Therapy ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
Randomized Controlled

Background. Prophylactic therapy with silymarin to prevent the development of antituberculosis drug-induced liver injury (anti-TB DILI) has been under debate. We aimed to evaluate the effect of silymarin in the prevention of anti-TB DILI. Methods. We searched MEDLINE, PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) up to 30th November 2018. Randomized controlled trials (RCTs) that compared silymarin and placebo to prevent anti-TB DILI were included. All statistical analyses were conducted using STATA 12.0 software. Standardized mean difference (SMD) and risk ratio (RR) with 95% confidence intervals (CIs) were used to evaluate the effect of silymarin. The quality of included studies was assessed according to Cochrane handbook. Funnel plots and Egger’s tests were carried out to evaluate publication bias. Sensitivity analysis was conducted to assess the influence of each study. Results. A total of 1198 patients from five RCTs (585 with silymarin and 613 with placebo groups) were included. Overall, silymarin significantly reduced the occurrence of anti-TB DILI at week 4 [RR: 0.33, 95% CI (0.15, 0.75)]. In addition, silymarin exerted protective effect on liver function in patients undergoing anti-TB drugs [SMD = − 0.15, 95% CI (−0.24, −0.07), P < 0.001 (ALT); SMD =−0.14, 95% CI (−0.23, −0.06), P = 0.001(AST); SMD =−0.12, 95% CI (−0.20, −0.03), P = 0.008 (ALP)]. Silymarin led to similar AEs in placebo groups [OR: 1.09, 95% CI (0.86, 1.39), P = 0.47]. Conclusion. Prophylactic therapy of silymarin is contributed to a noticeably reduced risk of development of anti-TB DILI four weeks after the initiation. In addition, silymarin significantly improved the liver function in patients who are receiving anti-TB drugs.

Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis

2010 ◽  
Vol 61 (4) ◽  
pp. 323-329 ◽  
Author(s):  
Wan Beom Park ◽  
Won Kim ◽  
Kook Lae Lee ◽  
Jae-Joon Yim ◽  
Moonsuk Kim ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Injury ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Drug Induced Liver Injury

FRI-085-Development and validation of a novel non-invasive model to predict drug-induced liver injury recurrence

2019 ◽  
Vol 70 (1) ◽  
pp. e421-e422
Author(s):  
Dong Ji ◽  
Chun-yan Wang ◽  
Shuai Wang ◽  
Zhong-bin Li ◽  
Ping Han ◽  
...  
Keyword(s):  
Liver Injury ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
Non Invasive ◽  
Development And Validation ◽  
Injury Recurrence

The association between HLA-DQB1 polymorphism and antituberculosis drug-induced liver injury: a Case-Control Study

2014 ◽  
Vol 40 (1) ◽  
pp. 110-115 ◽  
Author(s):  
R. Chen ◽  
Y. Zhang ◽  
S. Tang ◽  
X. Lv ◽  
S. Wu ◽  
...  
Keyword(s):  
Liver Injury ◽  
Case Control Study ◽  
Case Control ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
Control Study
Sign in / Sign up

Export Citation Format

Share Document